Atorvastatin prevents connexin43 remodeling in hypertrophied left ventricular myocardium of spontaneously hypertensive rats

Background  Connexin43 (Cx43) is the predominant gap junction protein in heart and is involved in the control of cell-to-cell communication to modulate the contractility and the electrical coupling of cardiac myocytes. Left ventricular (LV) hypertrophy is accompanied by changes of Cx43 expression. Recent studies have demonstrated that statins reduced cardiac hypertrophy. However, it is unknown whether statins can affect Cx43 expression in hypertrophied left ventricular myocardium. This study was designed to assess the effects of atorvastatin on LV hypertrophy and Cx43 expression in spontaneously hypertensive rats (SHR).
Methods  Nine-week old SHRs were randomly divided into two groups. Some received atorvastatin at 30 mg/kg by oral gavage once daily for 8 weeks (SHR-A); others received vehicle. Age-matched Wistar-Kyoto rats (WKY) received atorvastatin or vehicle for 8 weeks were used as controls. At the end of the experiment, we investigated LV hypertrophy and the expression of Cx43 in LV myocardium in four groups. Cx43 expression was investigated by the methods of Western blotting, immunohistochemistry, and transmission electron microscope. LV hypertrophy was accessed by pathological analysis and plasma brain natriuretic peptide (BNP) level.
Results  LV hypertrophy was prominent in untreated SHR. In SHR, LV myocardium Cx43 level was upregulated, and the distribution of Cx43 was displaced from their usual locations to other sites at various distances away from the intercalated disks. After atorvastatin treatment, myocardium Cx43 level was reduced in SHR-A, and the distribution of Cx43 gap junction became much regular and confined to intercalated disk. Statins also prevented LV hypertrophy in SHR.
Conclusions  These results provide novel in vivo evidence for the key role of Cx43 gap junctions in LV hypertrophy and the possible mechanism in anti-hypertrophic effect of statins. Atorvastatin treatment may have beneficial effects on LV hypertrophy in spontaneously hypertensive rats.

     

妊娠期高血压疾病并发脑血管病20例回顾性分析

目的 探讨妊娠期高血压疾病并发脑血管疾病的预防与治疗.方法 对20例妊娠合并脑血管疾病病例进行总结.结果 19例病人通过解痉、镇静、降压取得较好效果.结论 妊娠期高血压疾病并发脑血管病经积极治疗和早期预防,预后多良好.     

莱菔子水溶性生物碱逆转SHR心血管重构的实验研究

目的:探讨莱菔子水溶性生物碱对自发性高血压大鼠(SHR)的血压及心血管重构的影响.方法:将40只SHR随机分为5组:空白组、莱菔子水溶性生物碱高、中、低剂量组、卡托普利组,每组8只.采用尾动脉测压法测量血压,于给药8周后,摘取心脏,检测大鼠左室重量及心肌细胞直径、管壁厚/腔径比、管壁面积/腔径比等心血管重构指标.结果:莱菔子水溶性生物碱能明显降低SHR的血压,并使SHR的心室重构得到了改善.结论:莱菔子水溶性生物碱具有明显的降压作用,并对心血管重构具有逆转作用.     

肝细胞肝癌放射治疗研究进展

肝细胞肝癌（hepatocellular carcinoma,HCC）是世界范围内癌症死亡率较高的肿瘤之一。肝切除术（partial hepatectomy）是重要的治疗手段,然而,许多患者因肿瘤分期晚或潜在的慢性肝病和/或肝硬化不能接受肝切除术或肝移植术(liver transplantation)。此类患者,目前可选择肝动脉栓塞化疗（transarterial chemoembolization,TACE）、射频消融（radiofrequency ablation,RFA）、放射治疗、靶向治疗及免疫治疗等方法。肝癌诊断、治疗方式、对肝脏辐射耐受性的生物学理解和放疗技术的进步使得肝癌放射治疗的有效性和安全性都在不断提高,肝癌患者的生存和预后不断改善。     

肝癌中Ang-2的表达及其临床意义

目的探讨血管生成素2(Ang-2)与肿瘤的血管发生、入侵/转移能力和肝癌(HCC)预后之间的关系。方法采用免疫组织化学的方法检测Ang-2在肝癌、癌旁和正常肝组织中的表达。结果106例患者中,肝癌组织Ang2表达阳性的例数为63例(59.4%),Ang-2表达阳性的患者和表达阴性患者相比,很多方面有统计学差异(P<0.01),包括更低的组织学分期、门静脉侵犯(69.1%)等。Ang-2阳性表达的患者预后较差。结论肝癌Ang-2的表达和HCC的血管新生、入侵、恶性程度及疾病预后有关。     

盐酸乌拉地尔治疗98例高血压急症的效果及安全性评价

目的：评价静脉注射液盐酸乌拉地尔对高血压急症的疗效及安全性。方法：对98例高血压急症病人静脉注射盐酸乌拉地尔，观察用药前后血压，心率变化及用药前后不良反应。结果：血压在用药后5min明显下降，20-30rain达到高峰并保持稳定，心率无明显变化，无严重不良反应。结论：盐酸乌拉地尔治疗高血压急症安全、有效，为治疗高血压急症的理想药物。     

Portal tumor thrombus secondary to gastric carcinoma: report of a case with an emphasis on color Doppler ultrasound findings

We report the case of a 67-year-old woman with portal tumor thrombus (PTT) associated with gastric carcinoma. Abdominal ultrasound (US) revealed a marked thickening of the gastric wall and a mass lesion in the splenic vein. Color Doppler US showed the intraportal mass to be blood flow-poor and revealed a gastroepiploic vein extending from the splenic hilum to the portal confluence, passing behind the peritoneum. These findings corresponded well with gastric carcinoma with PTT. Endoscopy confirmed the presence of an advanced type II carcinoma predominantly located in the upper body, which yielded histological results consistent with a well-differentiated adenocarcinoma. The patient's general condition deteriorated rapidly, and she died 2 months later. To the best of our knowledge, this is the first report describing the presence of a large gastroepiploic vein secondary to gastric carcinoma-associated PTT.